<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7128205/results/search/funders/results.xml">
  <result pre="Infectious Diseases1201-97121878-3511The Authors. Published by Elsevier Ltd on behalf of" exact="International Society for Infectious Diseases." post="pmcid: 7128205S1201-9712(20)30076-X doi: 10.1016/j.ijid.2020.02.018 : Article Discovery and development"/>
  <result pre="BSAAs may end either being approved or dropped. The U.S" exact="Food and Drug Administration" post="(FDA) estimates that only 25â€“30% BSAA candidates that enter"/>
  <result pre="phase III are approved for use in the public (U.S" exact="Food and Drug Administration," post="2018). After approval and marketing of the drug, phase"/>
  <result pre="the drug in public, to surveil for rare effects (U.S" exact="Food and Drug Administration," post="2018, Umscheid et al., 2011). Forty-eight safe-in-man BSAAs undergo"/>
  <result pre="Burden of Disease Study 2017Lancet39220181789185830496104 Eurosurveillance EditorialT.Note from the editors:" exact="World Health Organization" post="declares novel coronavirus (2019-nCoV) sixth public health emergency of"/>
 </snippets>
</snippetsTree>
